This study reveals the deep mechanisms of interaction between lipid metabolism and the immune microenvironment in hepatocellular carcinoma, providing clear direction for designing combination therapeutic strategies targeting TAMs and metabolic pathways.
Literature Overview
This article, 'Multimodal sequencing identifies synergistic mechanisms driving resistance to neoadjuvant nivolumab treatment in hepatocellular carcinoma,' published in the journal Molecular Cancer, systematically explores the molecular and spatial immune mechanisms underlying resistance to neoadjuvant nivolumab therapy in patients with hepatocellular carcinoma (HCC). By integrating spatial transcriptomics, single-cell RNA sequencing, and lipidomics, the research team revealed that tumor-associated macrophages (TAMs), lipid-enriched tumor cells, and exhausted CD8+ T cells form physical and functional barriers at the tumor margin, thereby limiting immune cell infiltration. Furthermore, the study identified a critical role of the ADM-RAMP1-EBP signaling axis in mediating tumor cell lipid synthesis and immune escape, offering novel therapeutic targets to overcome resistance to immune checkpoint inhibitors.Background Knowledge
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide, with most patients diagnosed at an inoperable stage and poor prognosis in advanced cases. Although immune checkpoint inhibitors (e.g., anti-PD-1 antibody nivolumab) have significantly improved survival in some patients, overall response rates remain limited, and resistance mechanisms are not fully understood. Current understanding of TAM heterogeneity in HCC and their metabolic crosstalk with tumor cells remains insufficient, particularly lacking dynamic resolution in spatial context. The research bottleneck lies in how to systematically uncover the relationship between multicellular subpopulation interactions and metabolic reprogramming within the tumor immune microenvironment (TIME) while preserving spatial information. This study addresses this challenge using multimodal sequencing to precisely identify the synergistic mechanisms linking lipid metabolism dysregulation and immune exclusion phenotypes in non-responders, providing a theoretical foundation for developing predictive biomarkers and intervention targets.
Research Methods and Experiments
The research team enrolled a cohort of HCC patients receiving neoadjuvant nivolumab therapy and systematically compared differences in the tumor immune microenvironment between responders (R) and non-responders (NR) using bulk RNA-seq, spatial transcriptomics (ST-seq), and single-cell RNA-seq (scRNA-seq). By applying spatial transcriptomics, the authors mapped gene expression directly onto tissue sections, precisely delineating the enrichment of lipid synthesis-related genes at the tumor margin. Using non-negative matrix factorization (NMF) and BayesPrism deconvolution analysis, they further resolved the spatial distribution and functional states of tumor cells, TAMs, and CD8+ T cells across different regions. Additionally, survival analysis using TCGA data validated the association between lipidogenesis scores and patient prognosis, enhancing the clinical relevance of the findings.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides a mechanistic framework for precision immunotherapy in HCC, highlighting the synergistic role of metabolic reprogramming and immunosuppressive microenvironments. From a drug development perspective, the ADM-RAMP1-EBP axis offers new targets for small molecules or antibodies, particularly EBP—an essential enzyme in lipid synthesis—with high druggability. In clinical monitoring, spatial multi-omics features (e.g., lipid hotspots at tumor margins and TAM aggregation) could serve as tissue-based biomarkers to predict nivolumab efficacy. Moreover, this study supports incorporating lipid metabolism inhibitors into combination immunotherapies, advancing the field from 'single immune checkpoint' blockade toward dual 'microenvironment metabolism-immunity' interventions.
Conclusion
By leveraging multimodal sequencing, this study systematically uncovers the synergistic mechanisms underlying nivolumab resistance in hepatocellular carcinoma: tumor cells, driven by ADM signals from TAMs, enhance lipid synthesis via the RAMP1-EBP axis, forming an immune-excluded margin that impedes CD8+ T cell infiltration and promotes T cell exhaustion. This finding not only deepens our understanding of spatial heterogeneity within the TIME but also provides clinically actionable biomarkers and therapeutic targets. From bench to bedside, targeting the ADM-RAMP1-EBP signaling axis or its downstream lipid metabolic pathways may represent a novel strategy to overcome immunotherapy resistance. Notably, the combination of EBP inhibitors with anti-PD-1 therapy has demonstrated potent synergistic effects in mouse models, showing strong potential for rapid clinical translation. This study lays the foundation for establishing a 'metabolism-immunity' dual-targeting therapeutic paradigm, accelerating the transition of HCC treatment from empirical to mechanism-guided precision therapy.
